NDVA.H — Indiva Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -7.44% | ||
| Return on Equity | n/a | ||
| Operating Margin | -3.74% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.92 | 14.65 | 32.47 | 34.4 | 37.57 | 43.1 | 46.4 | 264.6% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Indiva Limited, through its indirect wholly owned subsidiary, Indiva Inc., is a Canada-based producer of cannabis servicing the medical and recreational markets. The Company is engaged in producing and selling cannabis products. It focuses on the production and processing of edible and extract cannabis products as well as packaging of edibles and extracts. Its brands include Pearls by Gron, Bhang Chocolate, Indiva Doppio Sandwich Cookies, Indiva 1432 Chocolate, and No Future Gummies and Vapes, as well as other Indiva branded extracts. Its product category includes edibles, capsules and tablets, and vape. Its edibles include Vanilla Double -Stuffed Chocolate Cookie, and Golden Vanilla Double Stuffed Cookie. The Company sells its cannabis products to consumers in the recreational market in the provinces of Ontario, British Columbia, Alberta, Quebec, Nova Scotia, Saskatchewan, Manitoba, New Brunswick, Prince Edward Island, Newfound.
Directors
- Carmine Marotta CEO
- Jennifer Welsh CFO
- Rob Carse COO
- Dave Paterson OTH
- Rachel Goldman DRC (49)
- Andre Lafleche IND
- John Marotta IND
- Hugh Sutherland IND
- Russell Wilson IND
- James Yersh IND
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- September 13th, 1979
- Public Since
- May 3rd, 1996
- No. of Employees
- 142
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 195,488,563
- Address
- 333 Preston Street, Suite 710, OTTAWA, K1S 5N4
- Web
- https://indiva.ca/
- Phone
- +1 6138838541
- Contact
- Anthony Simone
- Auditors
- Ernst & Young LLP
Upcoming Events for NDVA.H
Q1 2025 Indiva Ltd Earnings Release
Similar to NDVA.H
Khiron Life Sciences
TSX Venture Exchange
Lumiera Health
TSX Venture Exchange
Radient Technologies
TSX Venture Exchange
FAQ
What is the Indiva share price?
As of Today at 21:17 UTC, shares in Indiva are trading at CA$0.03. This share price information is delayed by 15 minutes.
How has the Indiva share price performed this year?
Shares in Indiva last closed at CA$0.03 and the price had moved by -25% over the past 365 days. In terms of relative price strength the Indiva share price has underperformed the Toronto Stock Exchange 300 Composite Index by -33.32% over the past year.
What are the analyst and broker recommendations for Indiva?
The overall consensus recommendation for Indiva is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Indiva dividend yield?
Indiva does not currently pay a dividend.
Does Indiva pay a dividend?
Indiva does not currently pay a dividend.
When does Indiva next pay dividends?
Indiva does not currently pay a dividend.
How do I buy Indiva shares?
To buy shares in Indiva you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Indiva?
As of the previous close price of CA$0.03, shares in Indiva had a market capitalisation of .
Where are Indiva shares listed?
Here are the trading details for Indiva:
- Country of listing: Canada
- Exchange: NEX
- Ticker Symbol: NDVA.H
What kind of share is Indiva?
Based on an overall assessment of its quality, value and momentum Indiva is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Indiva share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Indiva share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Indiva. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -64.91%.
As of the last closing price of CA$0.03, shares in Indiva were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Indiva PE Ratio?
The Indiva PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Indiva?
Indiva's management team is headed by:
- Carmine Marotta - CEO
- Jennifer Welsh - CFO
- Rob Carse - COO
- Dave Paterson - OTH
- Rachel Goldman - DRC
- Andre Lafleche - IND
- John Marotta - IND
- Hugh Sutherland - IND
- Russell Wilson - IND
- James Yersh - IND